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Emerging infections are receiving an increasing amount of both scientific and popular 
attention, with epidemics of Ebola virus in West Africa, and MERS Coronavirus in the 
Middle East. For these acute infections, the time between 'patient zero' and recognition 
of an epidemic was short. Conversely, epidemics caused by chronic infections, such as 
caused by human immunodeficiency virus type 1 (HIV-1), have taken much longer to 
recognise. HIV-1 was recognized in June 1981 in the United States (1), but emerged 
from primate reservoirs in Central Africa in the first half of the twentieth century (2). 
Given the scarcity of epidemiological data, sequence data have played a major role in 
consolidating our understanding of the emergence of HIV-1, as the evolutionary 
relatedness between viruses sampled from different individuals allows insights into the 
transmission dynamics of infection before the time of the first sample. Based on 
identification of genetically similar viruses in chimpanzees and gorillas in Cameroon, 
HIV-1 jumped from apes to humans at least four times (2), resulting in divergent groups 
of HIV-1 known as M, N, O and P. Given samples over a sufficient time span, the 
evolutionary rate of the virus can be estimated, which can then be used to infer the time 
to the most recent common ancestor, or TMRCA, of a set of viruses. This approach was 
used to estimate the TMRCA of group M HIV as being in the early 20th century (3). 
Sequence data can also be used to monitor changes in epidemiological dynamics over 
time, as larger epidemics tend to be associated with higher genetic diversity. Based on 
a diverse set of sequences from the Democratic Republic of Congo (DRC, formerly 
Zaire), this approach was used to show an increase in the epidemic growth rate in the 
1950s (4). Information on the geographical location of samples can be used to 
reconstruct spatial spread, which has argued that Kinshasa (formerly Leopoldville) in 
the DRC was the source of group M sequences that went on to seed the HIV-1 
pandemic (5). Furthermore, sequence data can be used to identify recombinant viruses, 
which emerge when an individual is infected with two or more viral strains; the high 
frequency of recombinant viruses from Kinshasa in the 1980s suggests that 
transmission was occurring at a high rate (6). Yet despite these insights, sequence data 
alone cannot tell us the causes for this spread. 
Why did HIV-1 emerge in Central Africa? Given the presence of multiple simian 
immunodeficiency viruses in different primate species in Africa (7), as well as the 
increasing amount of contact with wildlife during the Scramble for Africa, with the 
cultivation of cash crops and the exploitation of natural resources (8). However, human-
to-human transmission is required in order for a cross-species transmission event to 
result in an epidemic, and during the earliest stages of an epidemic, the infection may 
well 'fade out' due to chance. The routes of transmission of HIV are well characterised, 
yet their epidemiological importance in Africa has remained controversial. This 
controversy stems in part from the low probability of transmission of HIV per sexual 
contact (10). It is only with repeated exposures to an infected person that the cumulative 
risk of transmission becomes significant. The exception to this is during primary HIV 
infection, when the infectivity is higher; with high rates of partner change, chains of 
more efficient transmission involving primary infection may occur. This may have 
contributed to the rapid emergence of HIV among female sex workers in Nairobi, where 
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the prevalence rose from 4% in 1981 to 61% in 1985 (11). In contrast, infection via the 
parenteral route is more efficient, even in chronic infection (12). 
What caused HIV-1 to emerge? Early modeling work (13) investigated two possible 
explanations for how HIV transmission may increase sharply. Firstly, a spatially 
heterogeneous model where the population is divided into villages can give rise to an 
increase in the epidemic growth rate, without any change in the epidemiological 
characteristics of the model. However, the increase in growth rate probably occurred in 
an urban environment, rather than an interconnected network of villages. Secondly, 
even a modest increase in contact rate can lead to greatly increased transmission rates, 
as more transmissions occur during acute HIV infection, when infectivity is high. One 
proposed pathway of increased contact rates is that iatrogenic transmission played a 
role in 'jumpstarting' the epidemic. The high rate of transmission of HIV via blood or 
contaminated needles (12), coupled with the potentially high number of exposures to a 
single infected needle could potentially amplify a small number of cases into a large 
number, capable of sustaining further transmission. Western style biomedicine was 
used as a tool of empire by the colonial powers, and the 1950s was a time of 
widespread biomedical interventions, including injections for treatment of tuberculosis, 
sleeping sickness, syphilis, and yaws. Some have argued that iatrogenic transmission 
must have been important in the very earliest stages of HIV-1 emergence from primate 
reservoirs (14). A competing, although non-exclusive, pathway is sexual transmission; 
high rates of sex work that accompanied urbanisation following World War II may have 
boosted HIV-1 prevalence. 
In this issue of the Journal of Infectious Diseases, Hogan et al. (15) present evidence 
that iatrogenic exposure may have played a role in the apparently rapid increase of HIV-
1 in the 1950s in Kinshasa, using a combination of viral sequence, serological and 
epidemiological survey data relating to two other chronic infections - hepatitis C virus 
(HCV) and human T cell lymphotropic virus 1 (HTLV-1). Elderly residents of Kinshasa, 
who may have been exposed to blood-borne viruses in the 1950s, were administered a 
questionnaire, and blood samples taken for serological testing and sequencing of HCV 
and HTLV-1. For two subtypes of HCV, 4k and 4r, sequence analysis demonstrated a 
burst of infection starting in the 1950s. Analysis of the serological and survey data 
demonstrated statistical associations of infection with HCV subtypes 4k and 4r, as well 
as HTLV, with potential iatrogenic exposure, particularly those reported to have occurred 
before 1960. A high proportion (12/26) of HTLV infected individuals were also infected 
with HCV, although the specific iatrogenic associations differed for the three different 
viruses, suggesting distinct but overlapping epidemics perhaps associated with 
transmission at different hospitals or clinics. The study team had used similar 
approaches elsewhere (16), but the focus on Kinshasa, the crucible where group M 
HIV-1 emerged makes it more relevant for studying pandemic HIV-1. 
The retrospective approach of Hogan et al. suffers from some unavoidable limitations. 
The sampling frame for the study was biased away from those individuals who had 
already died, such that HIV+ individuals and HCV+ individuals who had already 
developed cirrhosis or hepatocellular carcinoma are underrepresented. The sequence 
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analysis was also prone to bias due to the age of participants, which would inherently 
result in large 'effective population sizes' close to the present. Tips of the tree represent 
a combination of within-host. Although individuals co-infected with HCV and HTLV-1 
were overrepresented, suggesting that individuals may have been infected with both 
viruses at the same time, there was insufficient information in the sequence data to 
compare phylogenetic trees with confidence. The recall of events in the distant past is 
often prone to forward telescoping - thinking that an event occurred more recently than 
it actually happened, although Hogan et al. used events to anchor an individual in time, 
and hence minimise this effect. Despite these issues, the level of concordance in the 
survey and sequence data is reassuring. Another strength is that the sequence and 
survey data were collected from the same individuals, although it is difficult to integrate 
sequence data and behavioral data, and the sample size for phylogenetics was 
restricted to those infected, this was not a problem for HCV, as the prevalence was high 
(25.9%), but HTLV prevalence was much lower (3.1%) and may have limited statistical 
power. 
Why did group M viruses, which went on to become pandemic, emerge in Kinshasa, 
rather than Cameroon, where they presumably originated? Recent results on group O 
HIV-1 add to the puzzle. Like group M, group O originated in southern Cameroon, 
although from gorillas rather than chimpanzees (17), and like group M HIV-1 in Zaire, 
group O HIV-1 also underwent an increase in genetic diversity in the 1950s, consistent 
with an increasing epidemic (18). Unlike groups N and P, which are extremely rare and 
appear to have limited transmissibility, individuals infected with group O HIV-1 have a 
high viral load. Biomedical interventions were widespread in Cameroon, with rapid HCV 
diversification (19), consistent with epidemiological data demonstrating a cohort effect 
(20), with individuals born in 1940 having the highest HCV prevalence, and an 
association between trypanosomiasis treatment and HCV and HTLV infection amongst 
individuals 55 years and older (21). There may have been competition between group M 
and group O HIV-1, although individuals dually infected with groups M and O have been 
identified (22), or the emergence of HIV-1 in Zaire rather than Cameroon may simply 
reflect a founder effect, like those associated with HIV-1 epidemics outside of Africa. 
What about today? The widely held view is that sexual transmission is the predominant 
route, supported by mathematical models that exhibit relatively low rates of iatrogenic 
transmission (23) and a high risk associated with patterns of concurrency, although this 
remains contentious (24). Nevertheless, we should strive for the reduction of iatrogenic 
transmission, although there are barriers to be overcome in terms of provision of 
sufficient medical supplies and infrastructure, and improvements in biosecurity may be 
offset by the large reservoir of individuals harboring blood-borne viruses. In Egypt, 
which has the largest HCV epidemic in the world (27), probably as a result of 
parenteral-antischistosomal-therapy (PAT) mass-treatment campaigns (28), most new 
infections are iatrogenic in origin (29). 
What lessons should we glean from studies like Hogan et al.? All too often, such studies 
are erroneously interpreted or viewed with scepticism, such as following the publication 
of molecular epidemiological evidence implicating Haiti as a stepping stone for the 
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dissemination of HIV from Africa to the United States (31). Such studies should be 
treated more than a history lesson. Iatrogenic risks are not unique to Africa; Mongolia, 
for example, has a rate of hepatocellular carcinoma six times the global average, driven 
by high HCV and hepatitis B prevalence; while the exact reasons for the high 
prevalence of viral hepatitis are not known, epidemiological studies point to dental 
treatment as a risk factor (33). In an era of increasing population mobility, which drove 
the dissemination of HIV from Africa to the rest of the world, we have to take shared 
responsibility for development of health services and appropriate prevention strategies. 
With current discussions of vaccination to protect against Ebola virus (34), iatrogenesis 
should remain a concern in the global health agenda. 
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